Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HURA TuHURA Biosciences	$3.25 +6.6%	$2.58	$1.80 ▼ $8.63	$133.23M	0.04	522,862 shs	3.84 million shs
IGXT IntelGenx Technologies	$0.17	$0.17	$0.09 ▼ $0.22	$29.17M	2.47	N/A	N/A
OKYO OKYO Pharma	$2.96 -5.1%	$2.66	$0.85 ▼ $3.35	$117.35M	-0.09	209,075 shs	66,526 shs
SAVA Cassava Sciences	$2.32 +3.1%	$2.14	$1.15 ▼ $33.98	$108.69M	-2.05	865,496 shs	875,202 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HURA TuHURA Biosciences	+32.61%	+17.76%	+32.61%	-25.61%	+304,999,900.00%
IGXT IntelGenx Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
OKYO OKYO Pharma	-4.59%	0.00%	+11.03%	+118.18%	+213.57%
SAVA Cassava Sciences	+3.21%	-1.75%	+5.63%	+20.97%	-89.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HURA TuHURA Biosciences	1.2869 of 5 stars	3.7	0.0	0.0	0.0	1.1	0.0	0.0
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	2.8001 of 5 stars	3.5	5.0	0.0	0.0	2.0	1.7	0.0
SAVA Cassava Sciences	2.7294 of 5 stars	1.0	3.0	0.0	4.7	1.8	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HURA TuHURA Biosciences	3.40	Buy	$12.67	289.74% Upside
IGXT IntelGenx Technologies	0.00	N/A	N/A	N/A
OKYO OKYO Pharma	3.00	Buy	$7.00	136.49% Upside
SAVA Cassava Sciences	2.00	Hold	$2.00	-13.79% Downside

Current Analyst Ratings Breakdown

Latest IGXT, OKYO, HURA, and SAVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/23/2025	HURA TuHURA Biosciences	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/16/2025	HURA TuHURA Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
IGXT IntelGenx Technologies	$1.04M	28.05	N/A	N/A	($0.07) per share	-2.39
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HURA TuHURA Biosciences	-$21.68M	N/A	0.00	∞	N/A	N/A	291.69%	122.09%	10/6/2025 (Estimated)
IGXT IntelGenx Technologies	-$9.93M	-$0.06	N/A	∞	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$1.50	N/A	N/A	N/A	N/A	-87.72%	-72.05%	8/14/2025 (Estimated)

Latest IGXT, OKYO, HURA, and SAVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	HURA TuHURA Biosciences	-$0.13	-$0.15	-$0.02	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
IGXT IntelGenx Technologies	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HURA TuHURA Biosciences	N/A	3.00	3.00
IGXT IntelGenx Technologies	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	0.40	0.40
SAVA Cassava Sciences	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HURA TuHURA Biosciences	0.62%
IGXT IntelGenx Technologies	N/A
OKYO OKYO Pharma	2.97%
SAVA Cassava Sciences	38.05%

Insider Ownership

Company	Insider Ownership
HURA TuHURA Biosciences	0.20%
IGXT IntelGenx Technologies	42.05%
OKYO OKYO Pharma	40.46%
SAVA Cassava Sciences	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HURA TuHURA Biosciences	N/A	43.68 million	43.59 million	N/A
IGXT IntelGenx Technologies	38	174.66 million	101.21 million	Not Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable
SAVA Cassava Sciences	30	48.31 million	42.41 million	Optionable

IGXT, OKYO, HURA, and SAVA Headlines

Recent News About These Companies

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

August 7, 2025 | globenewswire.com

Ginkgo Bioworks Holdings Q2 Earnings Preview

August 6, 2025 | msn.com

Cassava Sciences Announces Positive Preclinical Results

August 6, 2025 | theglobeandmail.com

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

August 4, 2025 | globenewswire.com

Gallacher Capital Management LLC Decreases Stock Holdings in Cassava Sciences, Inc. (NASDAQ:SAVA)

July 23, 2025 | marketbeat.com

SAVA - Cassava Sciences Inc Sustainability - Morningstar

July 2, 2025 | morningstar.comM

Cassava Sciences presents poster at TSC 2025 on Simufilam

June 30, 2025 | msn.com

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

June 30, 2025 | globenewswire.com

SAVA Stock Price for Cassava Sciences Inc - Morningstar

June 28, 2025 | morningstar.comM

Why cassava could be a great addition to a balanced diet

June 26, 2025 | msn.com

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava partners with Zindi to give African AI developers better tools

May 15, 2025 | techzim.co.zwT

Cassava Sciences Inc.

May 15, 2025 | barrons.com

5 ON YOUR SIDE: Lead levels in cassava flour

May 15, 2025 | kstp.comK

Cassava Technologies, Zindi collaborate on AI services

May 12, 2025 | msn.com

Cassava Technologies and Zindi collaborate to showcase African A.I. innovation

May 12, 2025 | thezimbabwemail.comT

Cassava Technologies and Zindi Partner to Supercharge Africa’s AI and GPU Ecosystem

May 12, 2025 | devdiscourse.comD

New report finds concerning levels of lead in popular cassava items

May 12, 2025 | yahoo.com

Cassava takes next step for African AI

May 12, 2025 | htxt.co.zaH

Cassava Technologies and Zindi collaborate to showcase African Artificial Intelligence (AI) innovation

May 12, 2025 | zawya.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGXT, OKYO, HURA, and SAVA Company Descriptions

TuHURA Biosciences NASDAQ:HURA

$3.25 +0.20 (+6.56%)

Closing price 04:00 PM Eastern

Extended Trading

$3.21 -0.04 (-1.26%)

As of 08:00 PM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

IntelGenx Technologies OTCMKTS:IGXT

$0.17 0.00 (0.00%)

As of 05/27/2025

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

OKYO Pharma NASDAQ:OKYO

$2.96 -0.16 (-5.13%)

Closing price 03:59 PM Eastern

Extended Trading

$2.92 -0.04 (-1.35%)

As of 07:52 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Cassava Sciences NASDAQ:SAVA

$2.32 +0.07 (+3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$2.34 +0.02 (+0.65%)

As of 07:58 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time